CLASS ACTION UPDATE for AYX, FENC and TCMD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / October 13, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AYX Shareholders Click Here: https://www.zlk.com/pslra-1/alteryx-inc-information-request-form?prid=10085&wire=1
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-information-request-form?prid=10085&wire=1
TCMD Shareholders Click Here: https://www.zlk.com/pslra-1/tactile-systems-technology-inc-loss-submission-form?prid=10085&wire=1

* ADDITIONAL INFORMATION BELOW *

Alteryx, Inc. (NYSE:AYX)

AYX Lawsuit on behalf of: investors who purchased May 6, 2020 - August 7, 2020
Lead Plaintiff Deadline : October 19, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/alteryx-inc-information-request-form?prid=10085&wire=1

According to the filed complaint, during the class period, Alteryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was unable to close large deals within the quarter, and deals were pushed out to subsequent quarters or downsized; (2) as a result, Alteryx increasingly relied on adoption licenses to attract new customers; (3) as a result and due to the nature of adoption licenses, the Company's revenue was reasonably likely to decline; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

FENC Lawsuit on behalf of: investors who purchased February 11, 2020 - August 10, 2020
Lead Plaintiff Deadline : November 2, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-information-request-form?prid=10085&wire=1

According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Tactile Systems Technology, Inc. (NASDAQ:TCMD)

TCMD Lawsuit on behalf of: investors who purchased May 7, 2018 - June 8, 2020
Lead Plaintiff Deadline : November 30, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tactile-systems-technology-inc-loss-submission-form?prid=10085&wire=1

According to the filed complaint, during the class period, Tactile Systems Technology, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile's pneumatic compression devices was materially smaller; (2) to induce sales growth and share gains, Tactile and/or its employees were engaged in illicit and illegal sales and marketing activities in violation of applicable federal and state rules and public payer regulations; (3) the foregoing illicit and illegal sales and marketing activities increased the risk of a Medicare audit of Tactile's claims and criminal and civil liability; (4) Tactile's revenues were in part the product of unlawful conduct and thus unsustainable; and that as a result of the foregoing, (5) Defendants' public statements, including Tactile's year-over-year revenue growth, the purported growth drivers, and the effectiveness of Tactile's internal controls over financial reporting were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/610347/CLASS-ACTION-UPDATE-for-AYX-FENC-and-TCMD-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.